aTyr Pharma マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Sanjay Shukla

最高経営責任者

US$1.3m

報酬総額

CEO給与比率	43.2%
CEO在任期間	7yrs
CEOの所有権	0.2%
経営陣の平均在職期間	5.9yrs
取締役会の平均在任期間	15.1yrs

経営陣の近況

Recent updates

CEO報酬分析

aTyr Pharma の収益と比較して、Sanjay Shukla の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$64m
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$1m	US$561k	-US$50m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$45m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$2m	US$561k	-US$45m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$41m
Mar 31 2022	n/a	n/a	-US$39m
Dec 31 2021	US$2m	US$510k	-US$34m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$25m
Dec 31 2020	US$1m	US$470k	-US$16m
Sep 30 2020	n/a	n/a	-US$17m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$664k	US$450k	-US$24m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$25m
Mar 31 2019	n/a	n/a	-US$30m
Dec 31 2018	US$1m	US$450k	-US$35m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$44m
Mar 31 2018	n/a	n/a	-US$45m
Dec 31 2017	US$2m	US$403k	-US$48m

報酬と市場: Sanjayの総報酬 ($USD 1.30M ) は、 German市場 ($USD 787.21K ) の同規模の企業の平均を上回っています。

報酬と収益: Sanjayの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sanjay Shukla (52 yo)

7yrs

在職期間

US$1,300,525

報酬

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sanjay Shukla	President	7yrs	US$1.30m	0.16% € 425.2k
Jill Broadfoot	Chief Financial Officer	6.3yrs	US$677.84k	0.025% € 64.8k
Nancy E. Krueger	General Counsel & Corporate Secretary	10.1yrs	US$651.28k	0.027% € 69.3k
Xiang-Lei Yang	Founder	no data	データなし	データなし
Jayant Aphale	Vice President of Technical Operations	less than a year	データなし	データなし
Ashlee Dunston	Director of Investor Relations & Corporate Communications	no data	データなし	データなし
Peter Villiger	Vice President of Corporate Development	4.8yrs	データなし	データなし
Danielle Campbell	VP of Human Resource	2.9yrs	データなし	データなし
Leslie Nangle	Vice President of Research	no data	データなし	データなし
Ying Buechler	Executive Director of Biologics Development & Manufacturing	no data	データなし	データなし
David King	Scientific Consultant	5.9yrs	US$717.31k	データなし

5.9yrs

平均在職期間

62yo

平均年齢

経験豊富な経営陣: 471Aの経営陣は経験豊富で経験豊富です（平均在職期間は5.9年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Sanjay Shukla	President	7yrs	US$1.30m	0.16% € 425.2k
John Clarke	Independent Director	19.2yrs	US$120.84k	0.024% € 61.6k
Paul Schimmel	Independent Director	19.2yrs	US$61.20k	1.31% € 3.4m
Floyd Bloom	Member of Scientific Advisory Board	15.1yrs	データなし	データなし
Bruce Beutler	Member of Scientific Advisory Board	15.3yrs	データなし	データなし
Benjamin Cravatt	Member of Scientific Advisory Board	no data	データなし	データなし
Timothy Coughlin	Independent Chairman of the Board	7.6yrs	US$92.20k	0.067% € 174.4k
Osamu Nureki	Member of Scientific Advisory Board	15.2yrs	データなし	データなし
Susan Ackerman	Member of Scientific Advisory Board	no data	データなし	データなし
Wing Wong	Member of Scientific Advisory Board	no data	データなし	データなし
Nancy Ip	Member of Scientific Advisory Board	no data	データなし	データなし
Jane Gross	Independent Director	5.3yrs	US$68.88k	0.0072% € 18.7k

15.1yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: 471Aの取締役会は経験豊富で経験豊富です ( 15.1年の平均在任期間)。

aTyr Pharma マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Independent Director recently bought €170k worth of stock

Independent Chairman of the Board recently bought €81k worth of stock

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Independent Director recently bought €410k worth of stock

Insufficient new directors

Insufficient new directors

Recent updates

New minor risk - Profitability

Independent Director recently bought €170k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Independent Chairman of the Board recently bought €81k worth of stock

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

New major risk - Share price stability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Independent Director recently bought €410k worth of stock

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Independent Director recently bought €163k worth of stock

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

New 90-day high: €6.35

aTyr Pharma, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

aTyr Pharma, Inc. to Report Q3, 2020 Results on Nov 12, 2020

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. announced that it expects to receive $20 million in funding from Aspire Capital Partners, LLC

aTyr Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34